MK-2866 vs Pramipexole
Moderate Research vs FDA Approved
synergistic Mechanism-based · 55% Pramipexole supports hormonal recovery from suppression caused by MK-2866. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Molecular Data
MK-2866 Pramipexole
Weight 389.33 Da 211.33 Da
Half-life ~24 hours ~8 hours
Type Non-steroidal selective androgen receptor modulator (C19H14F3N3O3) Non-ergoline dopamine D3 receptor agonist
Key Benefits
MK-2866
01 Increases lean body mass in a dose-dependent manner with clinical trial support
02 Preserves muscle mass during caloric deficit or catabolic conditions
03 Selective tissue activity reduces androgenic side effects compared to anabolic steroids
04 Oral bioavailability eliminates the need for injections
05 Does not aromatize to estrogen, avoiding gynecomastia and water retention
06 Improves physical function and stair-climbing power in clinical populations
07 Long 24-hour half-life allows convenient once-daily dosing
08 Mild side effect profile at commonly studied doses
Pramipexole
01 Suppresses prolactin elevation caused by 19-nor anabolic steroids
02 Non-ergoline structure eliminates the risk of cardiac valve fibrosis associated with ergot-derived agents like cabergoline
03 Generally cheaper and more widely available than cabergoline
04 FDA-approved with a well-characterized safety and pharmacokinetic profile
05 Can restore sexual function impaired by prolactin elevation on nandrolone or trenbolone cycles
06 Viable alternative when cabergoline cannot be sourced
Side Effects
MK-2866
Mild testosterone suppression (dose-dependent, typically 10-30% reduction at 25 mg)
HDL cholesterol reduction (10-20% suppression observed in clinical trials)
Headaches, particularly during the first 1-2 weeks
Mild back pain or muscle cramps
Transient fatigue toward the end of longer cycles
Slight reduction in libido at higher doses or extended cycle lengths
Pramipexole
Nausea (very common during initiation; typically resolves with continued use)
Drowsiness and somnolence (often taken at bedtime to manage this)
Dizziness or lightheadedness
Headache
Insomnia (in some users, despite drowsiness being more typical)
Orthostatic hypotension (feeling faint when standing up quickly)
Contraindications
Active liver disease or significantly elevated liver enzymes
Hormone-sensitive cancers (breast, prostate) without oncologist clearance
Pregnancy or breastfeeding (potential endocrine disruption to fetus/infant)
Individuals under 21 years of age (risk of premature HPTA disruption during development)
Concurrent use of hepatotoxic medications without liver function monitoring
Known hypersensitivity to MK-2866 or any formulation excipients
Competitive athletes subject to WADA or USADA anti-doping testing
Known hypersensitivity to pramipexole or any component of the formulation
Concurrent use of other dopamine agonists (cabergoline, bromocriptine)
History of impulse control disorders or pathological gambling
Severe renal impairment (pramipexole is primarily renally excreted; dose adjustment required in moderate impairment)
Concurrent use of dopamine antagonists (antipsychotics, metoclopramide) which oppose pramipexole's mechanism
Research Evidence
MK-2866 Pramipexole
Status Moderate Research FDA Approved
References 5 studies 5 studies
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.